Pharmacyclics’ Leukemia Drug Beats Glaxo’s in Head-to-Head Trial

May 31, 2014 1:12 PM

15 0

Pharmacyclics Inc. (PCYC:US)’s Imbruvica, introduced this year for chronic lymphocytic leukemia, helped patients live longer without their disease worsening than GlaxoSmithKline Plc’s treatment for the blood cancer.

In a head-to-head comparison, 391 patients whose leukemia had relapsed got either Imbruvica or Glaxo’s Arzerra. After six months, 88 percent of patients still taking Imbruvica hadn’t seen their cancer worsen, compared with 65 percent of those on Arzerra, according to research published in the New En...

Also read: NIH study shows how sex-specific reproductive systems arise

Read more

To category page